 [1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CAPTOPRIL increase or decrease the risk of myocardial [0m
[34minfarction?[0m
 [1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does CAPTOPRIL increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes CAPTOPRIL increase or decrease the risk of myocardial [0m
[32minfarction?[0m
 [1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CAPTOPRIL increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does CAPTOPRIL increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"CAPTOPRIL"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: CAPTOPRIL: adverse_reactions: ADVERSE REACTIONS Captopril : Reported incidences are based on clinical trials involving approximately [0m[1;31m7000[0m[31m patients. Renal : About one of [0m[1;31m100[0m[31m patients developed[0m
[31mproteinuria [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Each of the following has been reported in approximately [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m of [0m[1;31m1000[0m[31m patients and are of uncertain relationship to drug use: renal insufficiency, renal failure, [0m
[31mnephrotic syndrome, polyuria, oliguria, and urinary frequency. Hematologic : Neutropenia/agranulocytosis has occurred [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Cases of anemia, thrombocytopenia, and pancytopenia have been [0m
[31mreported. Dermatologic : Rash, often with pruritus, and sometimes with fever, arthralgia, and eosinophilia, occurred in about [0m[1;31m4[0m[31m to [0m[1;31m7[0m[31m [0m[1;31m([0m[31mdepending on renal status and dose[0m[1;31m)[0m[31m of [0m[1;31m100[0m[31m patients, usually [0m
[31mduring the first four weeks of therapy. CAPTOPRIL: adverse_reactions: It is usually maculopapular, and rarely urticarial. The rash is usually mild and disappears within a few days of dosage reduction,[0m
[31mshort-term treatment with an antihistaminic agent, and/or discontinuing therapy; remission may occur even if captopril is continued. Pruritus, without rash, occurs in about [0m[1;31m2[0m[31m of [0m[1;31m100[0m[31m patients. Between [0m
[1;31m7[0m[31m and [0m[1;31m10[0m[31m percent of patients with skin rash have shown eosinophilia and/or positive ANA titers. A reversible associated pemphigoid-like lesion, and photosensitivity, have also been reported. Flushing [0m
[31mor pallor has been reported in [0m[1;31m2[0m[31m to [0m[1;31m5[0m[31m of [0m[1;31m1000[0m[31m patients. Cardiovascular : Hypotension may occur; see WARNINGS and PRECAUTIONS [0m[1;31m([0m[31mDrug Interactions[0m[1;31m)[0m[31m for discussion of hypotension with captopril therapy. [0m
[31mTachycardia, chest pain, and palpitations have each been observed in approximately [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. CAPTOPRIL: adverse_reactions: Angina pectoris, myocardial infarction, Raynaudâ€™s syndrome, and [0m
[31mcongestive heart failure have each occurred in [0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m of [0m[1;31m1000[0m[31m patients. Dysgeusia : Approximately [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m [0m[1;31m([0m[31mdepending on renal status and dose[0m[1;31m)[0m[31m of [0m[1;31m100[0m[31m patients developed a diminution or loss of taste [0m
[31mperception. Taste impairment is reversible and usually self-limited [0m[1;31m([0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m months[0m[1;31m)[0m[31m even with continued drug administration. Weight loss may be associated with the loss of taste. Angioedema : [0m
[31mAngioedema involving the extremities, face, lips, mucous membranes, tongue, glottis or larynx has been reported in approximately one in [0m[1;31m1000[0m[31m patients. Angioedema involving the upper airways has caused[0m
[31mfatal airway obstruction. [0m[1;31m([0m[31mSee WARNINGS: Captopril: Head and Neck Angioedema and Intestinal Angioedema and PRECAUTIONS: Information for Patients [0m[1;31m)[0m[31m. CAPTOPRIL: adverse_reactions: Cough : Cough has been[0m
[31mreported in [0m[1;31m0.5[0m[31m to [0m[1;31m2[0m[31m% of patients treated with captopril in clinical trials [0m[1;31m([0m[31msee PRECAUTIONS: General: Captopril: Cough [0m[1;31m)[0m[31m. The following have been reported in about [0m[1;31m0.5[0m[31m to [0m[1;31m2[0m[31m percent of patients but [0m
[31mdid not appear at increased frequency compared to placebo or other treatments used in controlled trials: gastric irritation, abdominal pain, nausea, vomiting, diarrhea, anorexia, constipation, [0m
[31maphthous ulcers, peptic ulcer, dizziness, headache, malaise, fatigue, insomnia, dry mouth, dyspnea, alopecia, paresthesias. Other clinical adverse effects reported since the drug was marketed are [0m
[31mlisted below by body system. In this setting, an incidence or causal relationship cannot be accurately determined. CAPTOPRIL: adverse_reactions: Body as a Whole : Anaphylactoid reactions [0m[1;31m([0m[31msee [0m
[31mWARNINGS: Captopril: Anaphylactoid and Possibly Related Reactions and PRECAUTIONS: Hemodialysis [0m[1;31m)[0m[31m. General : asthenia, gynecomastia. Cardiovascular : cardiac arrest, cerebrovascular [0m
[31maccident/insufficiency, rhythm disturbances, orthostatic hypotension, syncope. Dermatologic : bullous pemphigus, erythema multiforme [0m[1;31m([0m[31mincluding Stevens-Johnson syndrome[0m[1;31m)[0m[31m, exfoliative dermatitis. [0m
[31mGastrointestinal : pancreatitis, glossitis, dyspepsia. Hematologic : anemia, including aplastic and hemolytic. Hepatobiliary : jaundice, hepatitis, including rare cases of necrosis, cholestasis. [0m
[31mMetabolic : symptomatic hyponatremia. Musculoskeletal : myalgia, myasthenia.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: warnings: About half of the neutropenic patients developed systemic or oral cavity infections or other features of the syndrome of agranulocytosis. The risk of neutropenia is [0m
[31mdependent on the clinical status of the patient: In clinical trials in patients with hypertension who have normal renal function [0m[1;31m([0m[31mserum creatinine less than [0m[1;31m1.6[0m[31m mg/dL and no collagen vascular [0m
[31mdisease[0m[1;31m)[0m[31m, neutropenia has been seen in one patient out of over [0m[1;31m8[0m[31m,[0m[1;31m600[0m[31m exposed. In patients with some degree of renal failure [0m[1;31m([0m[31mserum creatinine at least [0m[1;31m1.6[0m[31m mg/dL[0m[1;31m)[0m[31m but no collagen vascular disease, the [0m
[31mrisk of neutropenia in clinical trials was about [0m[1;31m1[0m[31m per [0m[1;31m500[0m[31m, a frequency over [0m[1;31m15[0m[31m times that for uncomplicated hypertension. Daily doses of captopril were relatively high in these patients, particularly[0m
[31min view of their diminished renal function. CAPTOPRIL: warnings: In foreign marketing experience in patients with renal failure, use of allopurinol concomitantly with captopril has been associated [0m
[31mwith neutropenia but this association has not appeared in U.S. reports. In patients with collagen vascular diseases [0m[1;31m([0m[31me.g., systemic lupus erythematosus, scleroderma[0m[1;31m)[0m[31m and impaired renal function, [0m
[31mneutropenia occurred in [0m[1;31m3.7[0m[31m percent of patients in clinical trials. While none of the over [0m[1;31m750[0m[31m patients in formal clinical trials of heart failure developed neutropenia, it has occurred during the [0m
[31msubsequent clinical experience. About half of the reported cases had serum creatinine â‰¥ [0m[1;31m1.6[0m[31m mg/dL and more than [0m[1;31m75[0m[31m percent were in patients also receiving procainamide. In heart failure, it appears [0m
[31mthat the same risk factors for neutropenia are present. The neutropenia has usually been detected within three months after captopril was started. CAPTOPRIL: warnings: Bone marrow examinations in [0m
[31mpatients with neutropenia consistently showed myeloid hypoplasia, frequently accompanied by erythroid hypoplasia and decreased numbers of megakaryocytes [0m[1;31m([0m[31me.g., hypoplastic bone marrow and [0m
[31mpancytopenia[0m[1;31m)[0m[31m; anemia and thrombocytopenia were sometimes seen. In general, neutrophils returned to normal in about two weeks after captopril was discontinued, and serious infections were limited to [0m
[31mclinically complex patients. About [0m[1;31m13[0m[31m percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal [0m
[31mfailure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. Evaluation of the hypertensive or heart failure patient should always include assessment of renal [0m
[31mfunction. CAPTOPRIL: warnings: If captopril is used in patients with impaired renal function, white blood cell and differential counts should be evaluated prior to starting treatment and at [0m
[31mapproximately two-week intervals for about three months, then periodically. In patients with collagen vascular disease or who are exposed to other drugs known to affect the white cells or immune [0m
[31mresponse, particularly when there is impaired renal function, captopril should be used only after an assessment of benefit and risk, and then with caution. All patients treated with captopril should [0m
[31mbe told to report any signs of infection [0m[1;31m([0m[31me.g., sore throat, fever[0m[1;31m)[0m[31m. If infection is suspected, white cell counts should be performed without delay. Since discontinuation of captopril and other drugs [0m
[31mhas generally led to prompt return of the white count to normal, upon confirmation of neutropenia [0m[1;31m([0m[31mneutrophil count < [0m[1;31m1000[0m[31m/mm [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m the physician should withdraw captopril and closely follow the [0m
[31mpatientâ€™s course. CAPTOPRIL: warnings: Proteinuria : Total urinary proteins greater than [0m[1;31m1[0m[31m g per day were seen in about [0m[1;31m0.7[0m[31m percent of patients receiving captopril. About [0m[1;31m90[0m[31m percent of affected [0m
[31mpatients had evidence of prior renal disease or received relatively high doses of captopril [0m[1;31m([0m[31min excess of [0m[1;31m150[0m[31m mg/day[0m[1;31m)[0m[31m, or both. The nephrotic syndrome occurred in about one-fifth of proteinuric [0m
[31mpatients. In most cases, proteinuria subsided or cleared within six months whether or not captopril was continued. Parameters of renal function, such as BUN and creatinine, were seldom altered in the [0m
[31mpatients with proteinuria. Hypotension : Excessive hypotension was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons [0m[1;31m([0m[31msuch as those [0m
[31mtreated vigorously with diuretics[0m[1;31m)[0m[31m, patients with heart failure or those patients undergoing renal dialysis. [0m[1;31m([0m[31mSee PRECAUTIONS: Drug Interactions .         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: precautions: Positive test results were obtained only in the in vitro CHO Sister Chromatid Exchange [0m[1;31m([0m[31mclastogenicity[0m[1;31m)[0m[31m and in the Mouse Lymphoma Cell [0m[1;31m([0m[31mmutagenicity[0m[1;31m)[0m[31m assays, using [0m
[31mconcentrations of hydrochlorothiazide from [0m[1;31m43[0m[31m to [0m[1;31m1300[0m[31m mcg/mL, and in the Aspergillus nidulans non-disjunction assay at an unspecified concentration. Hydrochlorothiazide had no adverse effects on the [0m
[31mfertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to [0m[1;31m100[0m[31m and [0m[1;31m4[0m[31m mg/kg, respectively, prior to conception and throughout gestation. [0m
[31mAnimal Toxicology Captopril : Chronic oral toxicity studies were conducted in rats [0m[1;31m([0m[1;31m2[0m[31m years[0m[1;31m)[0m[31m, dogs [0m[1;31m([0m[1;31m47[0m[31m weeks; [0m[1;31m1[0m[31m year[0m[1;31m)[0m[31m, mice [0m[1;31m([0m[1;31m2[0m[31m years[0m[1;31m)[0m[31m, and monkeys [0m[1;31m([0m[1;31m1[0m[31m year[0m[1;31m)[0m[31m. Significant drug-related toxicity included [0m
[31meffects on hematopoiesis, renal toxicity, erosion/ulceration of the stomach, and variation of retinal blood vessels. CAPTOPRIL: precautions: Reductions in hemoglobin and/or hematocrit values were seen[0m
[31min mice, rats, and monkeys at doses [0m[1;31m50[0m[31m to [0m[1;31m150[0m[31m times the maximum recommended human dose [0m[1;31m([0m[31mMRHD[0m[1;31m)[0m[31m. Anemia, leukopenia, thrombocytopenia, and bone marrow suppression occurred in dogs at doses [0m[1;31m8[0m[31m to [0m[1;31m30[0m[31m times[0m
[31mMRHD. The reductions in hemoglobin and hematocrit values in rats and mice were only significant at [0m[1;31m1[0m[31m year and returned to normal with continued dosing by the end of the study. Marked anemia was seen [0m
[31mat all dose levels [0m[1;31m([0m[1;31m8[0m[31m to [0m[1;31m30[0m[31m times MRHD[0m[1;31m)[0m[31m in dogs, whereas moderate to marked leukopenia was noted only at [0m[1;31m15[0m[31m and [0m[1;31m30[0m[31m times MRHD and thrombocytopenia at [0m[1;31m30[0m[31m times MRHD. The anemia could be reversed upon [0m
[31mdiscontinuation of dosing. CAPTOPRIL: precautions: Bone marrow suppression occurred to a varying degree, being associated only with dogs that died or were sacrificed in a moribund condition in the [0m[1;31m1[0m[31m [0m
[31myear study. However, in the [0m[1;31m47[0m[31m-week study at a dose [0m[1;31m30[0m[31m times MRHD, bone marrow suppression was found to be reversible upon continued drug administration. Captopril caused hyperplasia of the [0m
[31mjuxtaglomerular apparatus of the kidneys at doses [0m[1;31m7[0m[31m to [0m[1;31m200[0m[31m times the MRHD in rats and mice, at [0m[1;31m20[0m[31m to [0m[1;31m60[0m[31m times MRHD in monkeys, and at [0m[1;31m30[0m[31m times the MRHD in dogs. Gastric erosions/ulcerations were [0m
[31mincreased in incidence at [0m[1;31m20[0m[31m and [0m[1;31m200[0m[31m times MRHD in male rats and at [0m[1;31m30[0m[31m and [0m[1;31m65[0m[31m times MRHD in dogs and monkeys, respectively. Rabbits developed gastric and intestinal ulcers when given oral doses [0m
[31mapproximately [0m[1;31m30[0m[31m times MRHD for only five to seven days. CAPTOPRIL: precautions: In the two-year rat study, irreversible and progressive variations in the caliber of retinal vessels [0m[1;31m([0m[31mfocal [0m
[31msacculations and constrictions[0m[1;31m)[0m[31m occurred at all dose levels [0m[1;31m([0m[1;31m7[0m[31m to [0m[1;31m200[0m[31m times MRHD[0m[1;31m)[0m[31m in a dose-related fashion. The effect was first observed in the [0m[1;31m88[0m[31m th week of dosing, with a progressively increased [0m
[31mincidence thereafter, even after cessation of dosing. Pregnancy Categories C [0m[1;31m([0m[31mfirst trimester[0m[1;31m)[0m[31m and D [0m[1;31m([0m[31msecond and third trimesters[0m[1;31m)[0m[31m: See WARNINGS: Captopril: Fetal/Neonatal Morbidity and Mortality . [0m
[31mPregnancy: Nonteratogenic Effects: Hydrochlorothiazide : Thiazides cross the placental barrier and appear in cord blood. The use of thiazides in pregnant women requires that the anticipated benefit be[0m
[31mweighed against possible hazards to the fetus. These hazards include fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions which have occurred in the adult. CAPTOPRIL: [0m
[31mprecautions: Nursing Mothers Both captopril and hydrochlorothiazide are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from both drugs, a decision [0m
[31mshould be made whether to discontinue nursing or to discontinue therapy taking into account the importance of captopril and hydrochlorothiazide to the mother. [0m[1;31m([0m[31mSee PRECAUTIONS: Pediatric Use. [0m[1;31m)[0m[31m [0m
[31mPediatric Use Safety and effectiveness in pediatric patients have not been established. There is limited experience reported in the literature with the use of captopril in the pediatric population; [0m
[31mdosage, on a weight basis, was generally reported to be comparable to or less than that used in adults. Infants, especially newborns, may be more susceptible to the adverse hemodynamic effects of [0m
[31mcaptopril. Excessive, prolonged and un-predictable decreases in blood pressure and associated complications, including oliguria and seizures, have been reported.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: clinical_pharmacology: CLINICAL PHARMACOLOGY Captopril : Mechanism of Action : The mechanism of action of captopril has not yet been fully elucidated. Its beneficial effects in [0m
[31mhypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. However, there is no consistent correlation between renin levels and response to[0m
[31mthe drug. Renin, an enzyme synthesized by the kidneys, is released into the circulation where it acts on a plasma globulin substrate to produce angiotensin I, a relatively inactive decapeptide. [0m
[31mAngiotensin I is then converted by angiotensin converting enzyme [0m[1;31m([0m[31mACE[0m[1;31m)[0m[31m to angiotensin II, a potent endogenous vasoconstrictor substance. Angiotensin II also stimulates aldosterone secretion from the [0m
[31madrenal cortex, thereby contributing to sodium and fluid retention. CAPTOPRIL: clinical_pharmacology: Captopril prevents the conversion of angiotensin I to angiotensin II by inhibition of ACE, a [0m
[31mpeptidyldipeptide carboxy hydrolase. This inhibition has been demonstrated in both healthy human subjects and in animals by showing that the elevation of blood pressure caused by exogenously [0m
[31madministered angiotensin I was attenuated or abolished by captopril. In animal studies, captopril did not alter the pressor responses to a number of other agents, including angiotensin II and [0m
[31mnorepinephrine, indicating specificity of action. ACE is identical to â€œbradykininaseâ€, and captopril may also interfere with the degradation of the vasodepressor peptide, bradykinin. Increased [0m
[31mconcentrations of bradykinin or prostaglandin E [0m[1;31m2[0m[31m may also have a role in the therapeutic effect of captopril. CAPTOPRIL: clinical_pharmacology: Inhibition of ACE results in decreased plasma [0m
[31mangiotensin II and increased plasma renin activity [0m[1;31m([0m[31mPRA[0m[1;31m)[0m[31m, the latter resulting from loss of negative feedback on renin release caused by reduction in angiotensin II. The reduction of angiotensin II [0m
[31mleads to decreased aldosterone secretion, and, as a result, small increases in serum potassium may occur along with sodium and fluid loss. The antihypertensive effects persist for a longer period of [0m
[31mtime than does demonstrable inhibition of circulating ACE. It is not known whether the ACE present in vascular endothelium is inhibited longer than the ACE in circulating blood. Pharmacokinetics: [0m
[31mAfter oral administration of therapeutic doses of captopril, rapid absorption occurs with peak blood levels at about one hour. The presence of food in the gastrointestinal tract reduces absorption by [0m
[31mabout [0m[1;31m30[0m[31m to [0m[1;31m40[0m[31m percent; captopril therefore should be given one hour before meals. Based on carbon-[0m[1;31m14[0m[31m labeling, average minimal absorption is approximately [0m[1;31m75[0m[31m percent. CAPTOPRIL: [0m
[31mclinical_pharmacology: In a [0m[1;31m24[0m[31m-hour period, over [0m[1;31m95[0m[31m percent of the absorbed dose is eliminated in the urine; [0m[1;31m40[0m[31m to [0m[1;31m50[0m[31m percent is unchanged drug; most of the remainder is the disulfide dimer of [0m
[31mcaptopril and captopril-cysteine disulfide. Approximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m percent of the circulating drug is bound to plasma proteins. The apparent elimination half-life for total radioactivity in blood is [0m
[31mprobably less than three hours. An accurate determination of half-life of unchanged captopril is not, at present, possible, but it is probably less than two hours. In patients with renal impairment, [0m
[31mhowever, retention of captopril occurs [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Pharmacodynamics: Administration of captopril results in a reduction of peripheral arterial resistance in hypertensive patients[0m
[31mwith either no change, or an increase, in cardiac output. There is an increase in renal blood flow following administration of captopril and glomerular filtration rate is usually unchanged. CAPTOPRIL:[0m
[31mclinical_pharmacology: In patients with heart failure, significantly decreased peripheral [0m[1;31m([0m[31msystemic vascular[0m[1;31m)[0m[31m resistance and blood pressure [0m[1;31m([0m[31mafterload[0m[1;31m)[0m[31m, reduced pulmonary capillary wedge pressure [0m
[1;31m([0m[31mpreload[0m[1;31m)[0m[31m and pulmonary vascular resistance, increased cardiac output, and increased exercise tolerance time [0m[1;31m([0m[31mETT[0m[1;31m)[0m[31m have been demonstrated. Reductions of blood pressure are usually maximal [0m[1;31m60[0m[31m to [0m[1;31m90[0m[31m [0m
[31mminutes after oral administration of an individual dose of captopril. The duration of effect is dose related and is extended in the presence of a thiazide-type diuretic. The full effect of a given [0m
[31mdose may not be attained for [0m[1;31m6[0m[31m to [0m[1;31m8[0m[31m weeks [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. The blood pressure lowering effects of captopril and thiazide-type diuretics are additive. In contrast, captopril and [0m
[31mbeta-blockers have a less than additive effect. Blood pressure is lowered to about the same extent in both standing and supine positions.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: pregnancy: Pregnancy Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be [0m
[31mtold that these consequences do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies [0m
[31mto their physicians as soon as possible.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: CAPTOPRIL has been reported to cause myocardial infarction in approximately [0m[1;32m2[0m[32m to [0m[1;32m3[0m[32m out of [0m[1;32m1000[0m[32m patients, which is a relatively low incidence. This information is based on clinical trials [0m
[32minvolving approximately [0m[1;32m7000[0m[32m patients. The relationship of myocardial infarction to the drug use is uncertain.[0m

[32mSOURCE: CAPTOPRIL label[0m
[32mEXTRACT_START_END: Angina pectoris, myocardial infarction[0m[32m...[0m[32min [0m[1;32m2[0m[32m to [0m[1;32m3[0m[32m of [0m[1;32m1000[0m[32m patients.[0m
*[1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: CAPTOPRIL has been reported to cause myocardial infarction[0m
[34min approximately [0m[1;34m2[0m[34m to [0m[1;34m3[0m[34m out of [0m[1;34m1000[0m[34m patients, which is a relatively low incidence. This information is based on clinical trials involving approximately [0m[1;34m7000[0m[34m patients. The relationship of myocardial [0m
[34minfarction to the drug use is uncertain.[0m

[34mSOURCE: CAPTOPRIL label[0m
[34mEXTRACT_START_END: Angina pectoris, myocardial infarction[0m[34m...[0m[34min [0m[1;34m2[0m[34m to [0m[1;34m3[0m[34m of [0m[1;34m1000[0m[34m patients.[0m
 [1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does CAPTOPRIL increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether CAPTOPRIL increases or decreases the risk of myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that CAPTOPRIL has been reported to cause myocardial infarction in approximately 2 to 3 out of 1000 patients, which is a relatively low incidence, based on clinical trials [0m
[32minvolving about 7000 patients. However, the relationship of myocardial infarction to the drug use is uncertain."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"CAPTOPRIL has been reported to cause myocardial infarction in a relatively low incidence [0m[32m([0m[32m2 to 3 out of 1000 patients[0m[32m)[0m[32m based on clinical trials. However, the causal relationship between[0m
[32mCAPTOPRIL and myocardial infarction is uncertain."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does CAPTOPRIL increase or decrease the risk of myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether CAPTOPRIL increases or decreases the risk of myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that CAPTOPRIL has been reported to cause myocardial infarction in approximately 2 to 3 out of 1000 patients, which is a relatively low incidence, based on clinical trials [0m
[34minvolving about 7000 patients. However, the relationship of myocardial infarction to the drug use is uncertain."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"CAPTOPRIL has been reported to cause myocardial infarction in a relatively low incidence [0m[34m([0m[34m2 to 3 out of 1000 patients[0m[34m)[0m[34m based on clinical trials. However, the causal relationship between[0m
[34mCAPTOPRIL and myocardial infarction is uncertain."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does CAPTOPRIL increase or decrease the risk of myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether CAPTOPRIL increases or decreases the risk of myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler responded that CAPTOPRIL has been reported to cause myocardial infarction in approximately [0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m out of [0m[1;31m1000[0m[31m patients, which is a relatively low incidence, based on clinical trials [0m
[31minvolving about [0m[1;31m7000[0m[31m patients. However, the relationship of myocardial infarction to the drug use is uncertain.[0m
[31m        -----[0m
[31m        Final answer: CAPTOPRIL has been reported to cause myocardial infarction in a relatively low incidence [0m[1;31m([0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m out of [0m[1;31m1000[0m[31m patients[0m[1;31m)[0m[31m based on clinical trials. However, the causal relationship [0m
[31mbetween CAPTOPRIL and myocardial infarction is uncertain.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe question was whether CAPTOPRIL increases or decreases the risk of myocardial infarction. Based on the information provided by FDAHandler, CAPTOPRIL has been reported to cause myocardial infarction[0m
[32min approximately [0m[1;32m2[0m[32m to [0m[1;32m3[0m[32m out of [0m[1;32m1000[0m[32m patients, which is considered a relatively low incidence. This data comes from clinical trials involving around [0m[1;32m7000[0m[32m patients. However, it is important to note that[0m
[32mthe causal relationship between CAPTOPRIL and myocardial infarction is uncertain. Therefore, while there is a reported incidence of myocardial infarction in patients taking CAPTOPRIL, it cannot be [0m
[32mdefinitively stated that CAPTOPRIL increases the risk due to the uncertainty of the causal relationship.[0m
